Business Context and Reporting Period
Alnylam Pharmaceuticals, Inc. filed this Form 8-K on May 5, 2009, reporting a material event that occurred on April 29, 2009. The filing details the entry into an amended and restated collaboration and license agreement with Isis Pharmaceuticals, Inc., expanding their partnership to focus on single-stranded RNAi (ssRNAi) technology.
Key Financial Metrics
This filing reports on a specific contractual agreement rather than periodic financial performance. Consequently, the document does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
- Upfront License Fee: $11.0 million payable on signing.
- Total Potential License Fees: Up to $31.0 million payable in four tranches.
- Annual Research Funding: Minimum of $3.0 million per year for three years.
- Potential Milestones: Up to $18.5 million per product if Alnylam develops and commercializes ssRNAi drugs.
- Sublicense Royalties: Isis eligible for up to 50% of sublicense payments initially; Alnylam eligible for up to 5% of Isis sublicense payments.
Material Changes
The primary material change is the superseding of the March 11, 2004 collaboration agreement. The new agreement expands the scope of collaboration to include ssRNAi technology while extending the existing cross-licensing arrangement for double-stranded RNAi. Alnylam obtained a co-exclusive, worldwide license to Isis's patents regarding chemistry and RNA-targeting mechanisms for designated gene targets.
Outlook, Risks, and Contingencies
Management Commentary and Terms: Both parties will discover and develop drugs using ssRNAi technology. The agreement includes specific performance milestones tied to in vivo efficacy in rodents and non-human primates, as well as the initiation of clinical trials.
Termination Rights: Alnylam retains the unilateral right to terminate the research program before September 30, 2010. Upon such termination, licenses and payment obligations for ssRNAi products would cease. Either party may terminate for material breach after a 90-day cure period or in the event of specified bankruptcy events.
Risks: Future payments are contingent upon achieving specific scientific and clinical milestones. The agreement's duration is tied to the expiration of the last-to-expire licensed patent.
Investor Verification Checklist
- Verify the specific gene targets designated by Alnylam for the ssRNAi license.
- Confirm the cash impact of the $11.0 million upfront payment on the company's current liquidity position.
- Monitor progress toward the $10.0 million milestone contingent on in vivo efficacy in rodents within 18 months.
- Review the terms regarding the decline of Isis's 50% share of sublicense payments over time.
- Assess the implications of Alnylam's unilateral termination right expiring on September 30, 2010.